Time‐Dependent Interaction Between Lopinavir/Ritonavir and Fexofenadine
- 1 July 2006
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 46 (7), 758-767
- https://doi.org/10.1177/0091270006288733
Abstract
This study investigated the effect of single-dose and steady-state lopinavir/ritonavir on the exposure to fexofenadine, as a measure of P-glycoprotein activity. Sixteen volunteers (8 women) received single-dose oral fexofenadine 120 mg alone, in combination with single-dose ritonavir 100 mg or lopinavir/ritonavir 400/100 mg (randomized 1:1, stratified by sex), and in combination with steady-state lopinavir/ritonavir 400/100 mg twice daily. Single-dose ritonavir and lopinavir/ritonavir increased the area under the fexofenadine plasma concentration-time curve from 0 to infinity (AUC(infinity)) by 2.2- and 4.0-fold, respectively (P < .02). Steady-state lopinavir/ritonavir increased the fexofenadine AUC(infinity) by 2.9-fold. No changes were observed in the fexofenadine elimination half-life (P > .12). The fexofenadine AUC(infinity) was increased by lopinavir/ritonavir, likely due to increased bioavailability secondary to P-glycoprotein inhibition. After repeated administration of lopinavir/ritonavir, the interaction was attenuated compared to the single-dose effect, although a net inhibitory effect was maintained. Time-dependent inhibition of P-glycoprotein by lopinavir/ritonavir should be considered when P-glycoprotein substrates are coadministered.Keywords
This publication has 32 references indexed in Scilit:
- Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)British Journal of Clinical Pharmacology, 2005
- Coordinate transcriptional regulation of bile acid homeostasis and drug metabolismArchives of Biochemistry and Biophysics, 2005
- Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humansFundamental & Clinical Pharmacology, 2004
- Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in ratsXenobiotica, 2004
- Digoxin toxicity and ritonavirAIDS, 2003
- LopinavirAIDS, 2003
- Lopinavir/RitonavirDrugs, 2003
- MDR1 gene polymorphisms and disposition of the P‐glycoprotein substrate fexofenadineBritish Journal of Clinical Pharmacology, 2002
- Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell lineJournal of Pharmaceutical Sciences, 2001
- Peptide Mimetic HIV Protease Inhibitors Are Ligands for the Orphan Receptor SXROnline Journal of Public Health Informatics, 2001